Sign In
Buy ALX
$281.63
-2.52 (-0.89%)
At Close: Jul 17, 2026
Is Alexander's (ALX) Outperforming Other Finance Stocks This Year?
10:40am, Thursday, 06'th Nov 2025
Here is how Alexander's (ALX) and Affiliated Managers Group (AMG) have performed compared to their sector so far this year.
ALX Oncology (ALXO) Expected to Announce Earnings on Friday
01:02am, Thursday, 06'th Nov 2025
ALX Oncology (NASDAQ: ALXO - Get Free Report) is expected to be posting its Q3 2025 results before the market opens on Friday, November 7th. Analysts expect ALX Oncology to post earnings of ($0.37) pe
Alexander's Announces Third Quarter Financial Results
09:17am, Monday, 03'rd Nov 2025
PARAMUS, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- ALEXANDER'S, INC. (New York Stock Exchange: ALX) filed its Form 10-Q for the quarter ended September 30, 2025 today and reported:
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline
Alexander's Breaks Above 8% Yield Territory
03:30pm, Wednesday, 29'th Oct 2025
In trading on Wednesday, shares of Alexander's were yielding above the 8% mark based on its quarterly dividend (annualized to $18), with the stock changing hands as low as $224.25 on the day. Dividend
Alexander's Declares Quarterly $4.50 Dividend on Common Shares
01:37pm, Wednesday, 29'th Oct 2025
PARAMUS, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) today announced that its Board of Directors has declared a regular quarterly dividend of $4.50 per share payable on Novem
-Two poster presentations showcase best- and first-in-class potential of ALX2004, a novel, antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors
KLP Kapitalforvaltning AS Lowers Position in Alexander’s, Inc. $ALX
03:02am, Wednesday, 22'nd Oct 2025
KLP Kapitalforvaltning AS lessened its holdings in Alexander's, Inc. (NYSE: ALX) by 79.2% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor ow
Alexander's Announces Third Quarter Earnings Release Date and Vornado Realty Trust Quarterly Conference Call
01:23pm, Tuesday, 21'st Oct 2025
PARAMUS, N.J., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) today announced that it will file its quarterly report on Form 10-Q for the quarter ended September 30, 2025 with the U.S
Mousetraps: 6 High-Yield REITs Risking Dividend Cuts
04:35pm, Friday, 10'th Oct 2025
High-yield REITs with low Dividend Safety grades often signal an elevated risk of dividend cuts and rapid share price declines, making them potential "mousetraps" for income investors. This article hi
New Strong Sell Stocks for September 22nd
08:26am, Monday, 22'nd Sep 2025
AHCO, ALX and CAG have been added to the Zacks Rank #5 (Strong Sell) List on September 22, 2025.
ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer
08:30am, Friday, 12'th Sep 2025
SOUTH SAN FRANCISCO, Calif., Sept. 12, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a
ALX Oncology to Participate in Upcoming Investor Conferences in September
12:00pm, Friday, 29'th Aug 2025
SOUTH SAN FRANCISCO, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline
- A potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors, ALX2004 is uniquely designed with every component optimized to maximize the ther
ALX Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update
04:05pm, Tuesday, 12'th Aug 2025
– Data from ASPEN-06 trial highlights CD47 expression as a key predictive biomarker of greater response to evorpacept in HER2+ Gastric Cancer; updated data to be presented at a medical conference in
